Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 678-686

  Hofner, Thomas ^a,b   Macher Goeppinger, Stephan ^a,b   Klein, Corinna ^a   Schillert, Anja ^a   Eisen, Christian ^a   Wagner, Steve ^a   Rigo Watermeier, Teresa ^a   Baccelli, Irène ^a   Vogel, Vanessa ^a   Trumpp, Andreas ^a   Sprick, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bladder cancer; CD24; CD44; CD47; Survival; Urothelial cancer

Indexed keywords

CD24 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER; CD44 PROTEIN, HUMAN; CD47 ANTIGEN; CD47 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STEM CELL; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENICITY; CELL POPULATION; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY; TUMOR XENOGRAFT; UROTHELIAL BLADDER CANCER; UROTHELIUM; ANIMAL; CANCER TRANSPLANTATION; COHORT ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LYMPH NODE METASTASIS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

AGED; ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, CD47; COHORT STUDIES; CYSTECTOMY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM TRANSPLANTATION; PROGNOSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84902544404     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.01.001     Document Type: Article

References (20)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
3. Chan K.S., Espinosa I., Chao M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009, 106:14016-14021.
4. Yeung T.M., Gandhi S.C., Wilding J.L., Muschel R., Bodmer W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A 2010, 107:3722-3727.
5. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
6. Kristiansen G., Pilarsky C., Wissmann C., et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005, 205:359-376.
7. Sagiv E., Starr A., Rozovski U., et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008, 68:2803-2812.
8. Huang L.R., Hsu H.C. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995, 55:4717-4721.
9. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
10. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
11. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011, 9:50-63.
12. Overdevest J.B., Knubel K.H., Duex J.E., et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A 2012, 109:E3588-E3596.
13. Brunner A., Prelog M., Verdorfer I., Tzankov A., Mikuz G., Ensinger C. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 2008, 61:307-310.
14. Macher-Goeppinger S., Aulmann S., Tagscherer K.E., et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res 2009, 15:650-659.
15. Huber J., Herpel E., Jakobi H., Hadaschik B.A., Pahernik S., Hohenfellner M. Two decades' experience with a prospective biobank for urologic oncology: research, clinical care, and the patients' view. Urol Oncol 2012, 31:990-996.
16. Gurel B., Iwata T., Koh C.M., et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008, 21:1156-1167.
17. Trumpp A., Wiestler O.D. Mechanisms of Disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 2008, 5:337-347.
18. Aigner S., Ramos C.L., Hafezi-Moghadam A., et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998, 12:1241-1251.
19. Aigner S., Sthoeger Z.M., Fogel M., et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997, 89:3385-3395.
20. Overdevest J.B., Thomas S., Kristiansen G., Hansel D.E., Smith S.C., Theodorescu D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 2011, 71:3802-3811.